Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections
IntroductionThe effect of tixagevimab/cilgavimab (Evusheld™; AstraZeneca, UK) should be evaluated in the context of concurrent outbreak situations.MethodsFor serologic investigation of tixagevimab/cilgavimab during the BA.5 outbreak period, sera of immunocompromised (IC) hosts sampled before and one...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1139980/full |
| _version_ | 1811161952568737792 |
|---|---|
| author | Jinyoung Yang Gunho Won Jin Yang Baek Jin Yang Baek Young Ho Lee Haein Kim Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Kyong Ran Peck Kyo Won Lee Jae Berm Park Sang Eun Yoon Seok Jin Kim Won Seog Kim Min Su Yim Kwangwook Kim Seokhwan Hyeon Byung Chul Kim Yoo-kyung Lee Jae-Hoon Ko |
| author_facet | Jinyoung Yang Gunho Won Jin Yang Baek Jin Yang Baek Young Ho Lee Haein Kim Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Kyong Ran Peck Kyo Won Lee Jae Berm Park Sang Eun Yoon Seok Jin Kim Won Seog Kim Min Su Yim Kwangwook Kim Seokhwan Hyeon Byung Chul Kim Yoo-kyung Lee Jae-Hoon Ko |
| author_sort | Jinyoung Yang |
| collection | DOAJ |
| description | IntroductionThe effect of tixagevimab/cilgavimab (Evusheld™; AstraZeneca, UK) should be evaluated in the context of concurrent outbreak situations.MethodsFor serologic investigation of tixagevimab/cilgavimab during the BA.5 outbreak period, sera of immunocompromised (IC) hosts sampled before and one month after tixagevimab/cilgavimab administration and those of healthcare workers (HCWs) sampled one month after a 3rd shot of COVID-19 vaccines, five months after BA.1/BA.2 breakthrough infection (BI), and one month after BA.5 BI were investigated. Semi-quantitative anti-spike protein antibody (Sab) test and plaque reduction neutralizing test (PRNT) against BA.5 were performed.ResultsA total of 19 IC hosts (five received tixagevimab/cilgavimab 300 mg and 14 received 600 mg) and 41 HCWs (21 experienced BA.1/BA.2 BI and 20 experienced BA.5 BI) were evaluated. Baseline characteristics did not differ significantly between IC hosts and HCWs except for age and hypertension. Sab significantly increased after tixagevimab/cilgavimab administration (median 130.2 BAU/mL before tixagevimab/cilgavimab, 5,665.8 BAU/mL after 300 mg, and 10,217 BAU/mL after 600 mg; both P < 0.001). Sab of one month after the 3rd shot (12,144.2 BAU/mL) or five months after BA.1/BA.2 BI (10,455.8 BAU/mL) were comparable with that of tixagevimab/cilgavimab 600 mg, while Sab of one month after BA.5 BI were significantly higher (22,216.0 BAU/mL; P < 0.001). BA.5 PRNT ND50 significantly increased after tixagevimab/cilgavimab administration (median ND50 29.6 before tixagevimab/cilgavimab, 170.8 after 300 mg, and 298.5 after 600 mg; both P < 0.001). The ND50 after tixagevimab/cilgavimab 600 mg was comparable to those of five months after BA.1 BI (ND50 200.9) while ND50 of one month after the 3rd shot was significantly lower (ND50 107.6; P = 0.019). The ND50 of one month after BA.5 BI (ND50 1,272.5) was highest among tested groups, but statistical difference was not noticed with tixagevimab/cilgavimab 600 mg.ConclusionTixagevimab/cilgavimab provided a comparable neutralizing activity against the BA.5 with a healthy adult population who were vaccinated with a 3rd shot and experienced BA.1/BA.2 BI. |
| first_indexed | 2024-04-10T06:22:14Z |
| format | Article |
| id | doaj.art-ebbfff69c33a4390ac032a4264dd855b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T06:22:14Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-ebbfff69c33a4390ac032a4264dd855b2023-03-02T04:43:25ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11399801139980Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infectionsJinyoung Yang0Gunho Won1Jin Yang Baek2Jin Yang Baek3Young Ho Lee4Haein Kim5Kyungmin Huh6Sun Young Cho7Cheol-In Kang8Doo Ryeon Chung9Kyong Ran Peck10Kyo Won Lee11Jae Berm Park12Sang Eun Yoon13Seok Jin Kim14Won Seog Kim15Min Su Yim16Kwangwook Kim17Seokhwan Hyeon18Byung Chul Kim19Yoo-kyung Lee20Jae-Hoon Ko21Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Vaccine Development Coordination, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of KoreaDivision of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaAsia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of KoreaDivision of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Transplantation Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Transplantation Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Vaccine Development Coordination, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of KoreaDivision of Vaccine Development Coordination, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of KoreaDivision of Vaccine Development Coordination, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of KoreaDivision of Vaccine Development Coordination, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of KoreaDivision of Vaccine Development Coordination, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of KoreaDivision of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaIntroductionThe effect of tixagevimab/cilgavimab (Evusheld™; AstraZeneca, UK) should be evaluated in the context of concurrent outbreak situations.MethodsFor serologic investigation of tixagevimab/cilgavimab during the BA.5 outbreak period, sera of immunocompromised (IC) hosts sampled before and one month after tixagevimab/cilgavimab administration and those of healthcare workers (HCWs) sampled one month after a 3rd shot of COVID-19 vaccines, five months after BA.1/BA.2 breakthrough infection (BI), and one month after BA.5 BI were investigated. Semi-quantitative anti-spike protein antibody (Sab) test and plaque reduction neutralizing test (PRNT) against BA.5 were performed.ResultsA total of 19 IC hosts (five received tixagevimab/cilgavimab 300 mg and 14 received 600 mg) and 41 HCWs (21 experienced BA.1/BA.2 BI and 20 experienced BA.5 BI) were evaluated. Baseline characteristics did not differ significantly between IC hosts and HCWs except for age and hypertension. Sab significantly increased after tixagevimab/cilgavimab administration (median 130.2 BAU/mL before tixagevimab/cilgavimab, 5,665.8 BAU/mL after 300 mg, and 10,217 BAU/mL after 600 mg; both P < 0.001). Sab of one month after the 3rd shot (12,144.2 BAU/mL) or five months after BA.1/BA.2 BI (10,455.8 BAU/mL) were comparable with that of tixagevimab/cilgavimab 600 mg, while Sab of one month after BA.5 BI were significantly higher (22,216.0 BAU/mL; P < 0.001). BA.5 PRNT ND50 significantly increased after tixagevimab/cilgavimab administration (median ND50 29.6 before tixagevimab/cilgavimab, 170.8 after 300 mg, and 298.5 after 600 mg; both P < 0.001). The ND50 after tixagevimab/cilgavimab 600 mg was comparable to those of five months after BA.1 BI (ND50 200.9) while ND50 of one month after the 3rd shot was significantly lower (ND50 107.6; P = 0.019). The ND50 of one month after BA.5 BI (ND50 1,272.5) was highest among tested groups, but statistical difference was not noticed with tixagevimab/cilgavimab 600 mg.ConclusionTixagevimab/cilgavimab provided a comparable neutralizing activity against the BA.5 with a healthy adult population who were vaccinated with a 3rd shot and experienced BA.1/BA.2 BI.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1139980/fullCOVID-19SARS-CoV-2Evusheldneutralizing antibodyBA.5 variant |
| spellingShingle | Jinyoung Yang Gunho Won Jin Yang Baek Jin Yang Baek Young Ho Lee Haein Kim Kyungmin Huh Sun Young Cho Cheol-In Kang Doo Ryeon Chung Kyong Ran Peck Kyo Won Lee Jae Berm Park Sang Eun Yoon Seok Jin Kim Won Seog Kim Min Su Yim Kwangwook Kim Seokhwan Hyeon Byung Chul Kim Yoo-kyung Lee Jae-Hoon Ko Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections Frontiers in Immunology COVID-19 SARS-CoV-2 Evusheld neutralizing antibody BA.5 variant |
| title | Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections |
| title_full | Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections |
| title_fullStr | Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections |
| title_full_unstemmed | Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections |
| title_short | Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections |
| title_sort | neutralizing activity against omicron ba 5 after tixagevimab cilgavimab administration comparable to those after omicron ba 1 ba 2 breakthrough infections |
| topic | COVID-19 SARS-CoV-2 Evusheld neutralizing antibody BA.5 variant |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1139980/full |
| work_keys_str_mv | AT jinyoungyang neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT gunhowon neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT jinyangbaek neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT jinyangbaek neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT youngholee neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT haeinkim neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT kyungminhuh neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT sunyoungcho neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT cheolinkang neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT dooryeonchung neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT kyongranpeck neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT kyowonlee neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT jaebermpark neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT sangeunyoon neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT seokjinkim neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT wonseogkim neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT minsuyim neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT kwangwookkim neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT seokhwanhyeon neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT byungchulkim neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT yookyunglee neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections AT jaehoonko neutralizingactivityagainstomicronba5aftertixagevimabcilgavimabadministrationcomparabletothoseafteromicronba1ba2breakthroughinfections |